Prevalence of Post-COVID-19 Condition in Adults 8.4 Percent in 2023
By Elana Gotkine HealthDay Reporter
THURSDAY, Dec. 26, 2024 -- The prevalence of post-COVID-19 condition (PCC) was 8.4 percent among U.S. adults in 2023, according to a research letter published online Dec. 13 in JAMA Network Open.
Anjel Vahratian, Ph.D., from the U.S. Centers for Disease Control and Prevention in Hyattsville, Maryland, and colleagues described the prevalence of PCC (ever and current) and self-reported limitations of activity due to symptoms of PCC using data from the 2023 National Health Interview Survey adult interview.
Among 29,522 respondents in 2023, 8.4, 3.6, and 2.3 percent reported that they had ever had PCC, currently had PCC, and currently had activity-limiting PCC, respectively. The researchers found that across all three outcomes, there were significant differences by sex, sexual orientation, age, race and Hispanic origin, family income, and urbanization. With increasing family income, there was a decrease in the percentage of adults who ever had PCC, currently had PCC, and currently had activity-limiting PCC. With increasing rurality of place of residence, the prevalence of these three outcomes increased. Overall, 64.5 percent of adults who currently had PCC experienced symptoms that were activity-limiting.
"This work supports the Department of Health and Human Services efforts to assess the overall disease burden of PCC across the U.S. population," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted December 2024
Further Support and Information on COVID-19
Read this next
Declining Childhood Vaccination May Increase Risk for Vaccine-Preventable Infections
WEDNESDAY, April 30, 2025 -- Declining childhood vaccination rates may increase outbreaks of eliminated vaccine-preventable infections within the United States, leading to a...
AACR: Incidence-Based Mortality Dropping for Young Women With Breast Cancer
TUESDAY, April 29, 2025 -- Incidence-based mortality (IBM) declined from 2010 to 2020 among women aged 20 to 49 years diagnosed with breast cancer, according to a study presented...
AACR: Nonsurgical Treatment Feasible for Mismatch Repair-Deficient Tumors
TUESDAY, April 29, 2025 -- A neoadjuvant programmed cell death 1 (PD-1) blockade enables nonoperative management among patients with early-stage mismatch repair-deficient (dMMR)...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.